Praxis Precision Medicines to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

Rhea-AI Summary

Praxis Precision Medicines (NASDAQ: PRAX) announced on February 22, 2022, that it will release its fourth quarter and full year 2021 financial results on February 28, 2022, prior to U.S. market opening. The company will provide a corporate update and report on recent business and pipeline advancements through a video presentation. Afterward, a live Q&A session will be held at 8:30 a.m. ET. Praxis focuses on developing therapies for CNS disorders linked to neuronal excitation-inhibition imbalance, with three clinical-stage product candidates.

Positive

• Upcoming financial results report scheduled for February 28, 2022.
• Focus on developing therapies for CNS disorders, indicating strong market potential.
• Three clinical-stage product candidates in the pipeline.

Negative

• None.

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will provide a corporate update and report financial results for the fourth quarter and full year 2021 on Monday, February 28, 2022, before the U.S. financial markets open. Management will provide a video update highlighting recent business and pipeline progress in conjunction with a press release. Subsequently, management will host a separate Q&A session via a live conference call and webcast at 8:30 a.m. ET.

Conference Call and Webcast Details:
US/Canada Toll-Free:	833-398-1037
International:	914-987-7735
Conference ID:	8993704
Webcast:	https://edge.media-server.com/mmc/p/dkhzv82n

A replay of the webcast will be available approximately two hours following its conclusion and will be archived for 30 days following the event, accessible through the Events & Presentations page of the Investors + Media section of Praxis’ website at https://investors.praxismedicines.com/events-and-presentations.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio with multiple programs, including product candidates across psychiatric disorders, movement disorders, epilepsy and other CNS indications, with three clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.

FAQ

When will Praxis Precision Medicines report its financial results?

Praxis will report its financial results for Q4 and full year 2021 on February 28, 2022.

What time is the Q&A session for Praxis Precision Medicines?

The Q&A session will take place at 8:30 a.m. ET on February 28, 2022.

What is the focus of Praxis Precision Medicines?

Praxis focuses on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

How many clinical-stage product candidates does Praxis have?

Praxis has three clinical-stage product candidates.